Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
19.62
+0.16 (0.82%)
Nov 10, 2026, 4:00 PM EST - Market closed
Braveheart Bio Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Braveheart Bio stock has a consensus rating of "Strong Buy" and an average price target of $45.25. The average 1-year stock price forecast is 130.63% higher than the current stock price, while the lowest is $40 (+103.87%) and the highest is $48 (+144.65%).
Price Target: $45.25 (+130.63%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Braveheart Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $45 | Buy | Maintains | $45 | +129.36% | Nov 9, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $40 | Buy | Maintains | $40 | +103.87% | Nov 7, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $48 | Buy | Maintains | $48 | +144.65% | Sep 9, 2026 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Aug 31, 2026 |
| Jefferies No rating | Jefferies | Buy Initiates $48 | Buy | Initiates | $48 | +144.65% | Aug 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.78
from -17.20
EPS Next Year
-1.62
from -1.78